modelTapentadol_Watson2019_reference
Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | tapentadol |
| ATC code: | N02AX06 |
| model: | one compartment, oral dosing (PK_1C_enteral) |
| source: | Watson E et al. 2019 |
| population: | pediatric patients (2 to <18 years) |
| measured compound: | tapentadol |
| review: | accepted with caveats |
| record page: | pharmacolibrary-docs |
Parameters as reported in the paper
| parameter | value | unit | meaning |
|---|---|---|---|
| CL/F (L/h) | 170 | L/h | CL/F |
| V/F (L) | 685 | L | V/F |
| Ka (h−1) | 2.03 | h−1 | kabs |
| TLAG (h) | 0.247 | h | tlag |
| theta_q319_wt_power | 0.638 | equation variable | |
| theta_q319_wt_power | 0.847 | equation variable |
About tapentadol
Tapentadol is an opioid painkiller used to treat moderate to severe pain, including pain associated with fibromyalgia. It is an approved medicine and is widely used as an analgesic, though it carries a boxed warning.
Summary written by glm-5.3-flash from Wikidata Q414463 and the WHO ATC classification; not checked by a person.
Identity, molar mass and metabolites: Tapentadol.
References
Watson E et al. (2019). Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. Journal of pain research 12:2835–2850. DOI:10.2147/JPR.S208454 PUBMED:31686902
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Real | Cl_ref | 4.722222222222223e-05 | Cl [m3/s] |
| Real | Vd_ref | 0.685 | Vd [m3] |
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.0009 | Volume of distribution per kg (default 0.9 L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 1 | bioavailability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 2.7777777777777776e-7 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1e-4 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
| Info › Therapeutic range (metadata, not used in equations) | |||
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | maximal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Info › Substance metadata | |||
| Modelica.Units.SI.MolarMass | MM (from PK_1C) | 0 | molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0) |
| Info › Substance metadata (not used in equations) | |||
| Pharmacolibrary.Types.Dose | LD50 (from PK_1C) | 0 | median lethal dose [mg/kg]; 0 = unknown |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models) |
Revisions
- 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Watson_2019: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: accepted with caveats